Published 3 days ago • loading... • Updated 3 days ago

Ritlecitinib Generally Well-Tolerated in Pediatric Patients with Alopecia, According to Phase 1 Study

Summary by dermatologytimes.com

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All

Left

Center

Right

dermatologytimes.com

Ritlecitinib Generally Well-Tolerated in Pediatric Patients with Alopecia, According to Phase 1 Study

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated2 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dermatologytimes.com broke the news in 3 days ago on Thursday, February 20, 2025.

Sources are mostly out of (0)

Ritlecitinib Generally Well-Tolerated in Pediatric Patients with Alopecia, According to Phase 1 Study

1 Articles

1 Articles

Ritlecitinib Generally Well-Tolerated in Pediatric Patients with Alopecia, According to Phase 1 Study

Ritlecitinib Generally Well-Tolerated in Pediatric Patients with Alopecia, According to Phase 1 Study

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics